2025
Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Oldham J, Neely M, Wojdyla D, Gulati M, Li P, Patel D, Palmer S, Todd J, Investigators I. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. CHEST Journal 2025 PMID: 40020995, DOI: 10.1016/j.chest.2025.02.018.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisLung transplantationLung function declinePulmonary fibrosisAssociated with 1.8-foldProgressive fibrosing interstitial lung diseaseMedian follow-up timeFibrosing interstitial lung diseaseFollow-up timeInterstitial lung diseaseCox proportional hazards modelsRisk of deathFunctional declineRisk of mortalityProportional hazards modelAntifibrotic treatmentThreshold of declineAssociated with lung function declineOutcomes RegistryLung diseaseEnrolling centersDLCOSmoking statusDiffusing capacityLung function
2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods.
Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, Spino C, Staszak S, Stauffer J, Wolters PJ, Cosgrove GP, Flaherty KR. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals Of The American Thoracic Society 2020, 17: 1620-1628. PMID: 32776789, PMCID: PMC12057645, DOI: 10.1513/annalsats.202001-035sd.Peer-Reviewed Original ResearchConceptsInterstitial lung diseasePatient RegistryClinician accessLarge multicenter registryMean diffusing capacityPositive smoking historyPercent of patientsIdiopathic pulmonary fibrosisTime of enrollmentIndividuals 18 yearsMulticenter registrySmoking historyPulmonary fibrosisSupplemental oxygenVital capacityLung diseaseMean agePatient populationAntifibrotic therapyApplicable biomarkersClinical informationDiffusing capacityPatientsClinical sitesRegistry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply